Forest Laboratories announces phase II caripazine results
1 October 2008 00:00 in Pharmaceutical Company Product News
Forest Laboratories and Gedeon Richter have announced positive phase II results of caripazine (RGH-188) in patients with acute mania associated with bipolar I disorder.
The preliminary top-line results of the study of the investigational antipsychotic achieved its primary endpoint, with patients showing significant symptom improvement compared to placebo on the Young Mania Rating Scale.
Forest Laboratories said this improvement was seen within the first week of treatment and at each time point subsequently studied.
It added further analyses of this data set would be completed in the near future, while the compound is also being studied in clinical trials in patients with schizophrenia.
Marco Taglietti, executive vice-president and chief medical officer of Forest Laboratories, said: "These exciting preliminary results in patients with bipolar mania demonstrate the potential of cariprazine as a novel antipsychotic agent."
He added the company would continue to assess and characterise the benefits of the compound, which is a unique molecule with high selectivity for the D3 dopamine receptors compared to the D2.
Last week, Forest Laboratories and Ironwood Pharmaceuticals announced plans to present phase IIb study results of linaclotide in patients with irritable bowel syndrome with constipation.
Other news stories from 01/10/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency